PACSA: Phase II study of pazopanib in patients with progressive recurrent or metastatic (R/M) salivary gland carcinoma (SGC).

Guigay, J.; Fayette, Jérôme; Even, Caroline; Cupissol, Didier; Rolland, Frédéric; Peyrade, Fréd́eric; Laguerre, Brigitte; Tourneau, Christophe Le; Zanetta, Sylvie; Moal, L. Bozec Le; Borel, Christian; Dô, Pascal; Digue, Laurence; Delaye, Jessy; Aupérin, Anne; Bidault, François; Costes, Valérie; Faivre, Laurence

doi:10.1200/jco.2016.34.15_suppl.6086

Cited by 23 publications

(15 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…50,52 Pazopanib, an oral small molecule inhibitor of vascular endothelial growth factor receptor, platelet-derived growth factor receptor, and KIT, was tested in the phase II trial PACSA. 53 This treatment seemed promising, with a 6-month PFS rate >40%. Nevertheless, among the 63 progressive recurrent or metastatic salivary gland carcinomas of this study, only 2 were salivary duct carcinomas.…”

Section: Discussionmentioning

confidence: 96%

Salivary duct carcinoma: Prospective multicenter study of 61 cases of the Réseau d'Expertise Français des Cancers ORL Rares

et al. 2018

View full text Add to dashboard Cite

Background The purposes of this study were to describe the characteristics of a prospective multicenter series of patients with salivary duct carcinoma and to investigate prognostic factors. Methods Patients included for salivary duct carcinoma between 2009 and 2016 in the Réseau d'Expertise Français des Cancers ORL Rares (REFCOR) database were selected. Immunohistochemical analyses were performed. Results Sixty‐one patients were included in this study. The primary site was the parotid gland in 90% of the cases. Fifty‐seven percent of the tumors were stage IV, 65% of patients had lymph node involvement, and 10% had metastases. Tumors showed androgen receptor (89%) and human epidermal growth factor receptor 2 (HER2)/neu (36%). Ninety‐four percent of patients underwent surgery and 86% had postoperative radiotherapy. Six patients were treated with targeted therapies. The 3‐year overall survival (OS) was 74% and the 3‐year disease‐free survival (DFS) was 44%. Tumor stages III to IV reduced DFS (hazard ratio [HR] 4.3; P = .04). The N2/3 class reduced distant metastasis‐free survival (HR 7.3; P = .007). Conclusion Salivary duct carcinoma prognosis is poor and is correlated with tumor stage and lymph node classification. Androgen receptor and HER2/neu should be tested as they offer the possibility of targeted therapies.

show abstract

Section: Discussionmentioning

confidence: 96%

Salivary duct carcinoma: Prospective multicenter study of 61 cases of the Réseau d'Expertise Français des Cancers ORL Rares

et al. 2018

View full text Add to dashboard Cite

show abstract

“…In a phase II study that required documented disease progression prior to enrollment, pazopanib – a multi-kinase inhibitor of VEGFR, PDGFR, and KIT – resulted in prolonged stable disease in both ACC adenoid cystic and non-ACC patients. Although the response rate was low (two responders – 1 ACC and one non-ACC), the trial met its primary endpoint of 6-month PFS greater than 40 % [38]. Similarly a trial of nintedanib targeting VEGFR1-3, PDGFRα/β, and FGFR1-2 had a disease control rate of 75 % and a 6-month PFS >60 %, although it was not clear if disease progression was required prior to enrollment [39].…”

Section: Biologic Agentsmentioning

confidence: 99%

Systemic therapy for recurrent or metastatic salivary gland malignancies

2016

View full text Add to dashboard Cite

Salivary gland carcinomas are notoriously resistant to therapy and no standard of care exists. Due to the rarity of these malignancies, various histologies, and wide ranging clinical behavior it has been difficult to standardize systemic therapy. We have reviewed clinical prospective studies in the last 15 years with salivary gland malignancies involving cytotoxic chemotherapy and biologic agents including targeted therapies such as anti-HER-2, anti-EGFR therapies, and therapies directed at c-kit. Although the results of most trials are modest at best, there has been an increase in studies for salivary cancer in recent years and there are several promising treatment approaches in evolution. Every effort should be made to treat salivary gland malignancies under a clinical protocol and/or at a large multidisciplinary practice with clinicians experienced in treating these malignancies.

show abstract

“…Pazopanib, a small molecule inhibitor of VEGFR, PDGFR, and KIT, has previously been assessed for antitumor activity in ACC patients with underwhelming results, including 1 of 46 patients demonstrating a partial response and 35 of 46 with stable disease [ 24 ]. The median progression-free survival and overall survival were reported at 5.9 months and 16.6 months, respectively.…”

Section: Resultsmentioning

confidence: 99%

A Contemporary Review of Molecular Therapeutic Targets for Adenoid Cystic Carcinoma

Miller

Mokhtari

et al. 2022

Cancers

View full text Add to dashboard Cite

ACC is a rare malignant tumor of the salivary glands. In this contemporary review, we explore advances in identification of targetable alterations and clinical trials testing these druggable targets. A search of relevant articles and abstracts from national meetings and three databases, including PubMed, Medline, and Web of Science, was performed. Following keyword search analysis and double peer review of abstracts to ensure appropriate fit, a total of 55 manuscripts were included in this review detailing advances in molecular targets for ACC. The most researched pathway associated with ACC is the MYB–NFIB translocation, found to lead to dysregulation of critical cellular pathways and thought to be a fundamental driver in a subset of ACC disease pathogenesis. Other notable molecular targets that have been studied include the cKIT receptor, the EGFR pathway, and NOTCH1, all with limited efficacy in clinical trials. The ongoing investigation of molecular abnormalities underpinning ACC that may be responsible for carcinogenesis is critical to identifying and developing novel targeted therapies.

show abstract

PACSA: Phase II study of pazopanib in patients with progressive recurrent or metastatic (R/M) salivary gland carcinoma (SGC).

Cited by 23 publications

References 0 publications

Salivary duct carcinoma: Prospective multicenter study of 61 cases of the Réseau d'Expertise Français des Cancers ORL Rares

Salivary duct carcinoma: Prospective multicenter study of 61 cases of the Réseau d'Expertise Français des Cancers ORL Rares

Systemic therapy for recurrent or metastatic salivary gland malignancies

A Contemporary Review of Molecular Therapeutic Targets for Adenoid Cystic Carcinoma

Contact Info

Product

Resources

About